Uterine Leiomyoma (Uterine Fibroids) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Uterine leiomyoma (uterine fibroids) clinical trials market research report provides top line data relating to the clinical trials on uterine leiomyoma (uterine fibroids). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
Key Regions In The Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market
The key regions in the uterine leiomyoma (uterine fibroids) clinical trials market are North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America and others. Asia -Pacific has the highest number of clinical trials.
Uterine leiomyoma (uterine fibroids) clinical trials market in Asia-Pacific
Australia, India, China, Japan, and South Korea are the key countries in the Asia-Pacific region in the uterine leiomyoma (uterine fibroids) clinical trials market. Among them China has the highest number of clinical trials.
Uterine leiomyoma (uterine fibroids) clinical trials market in Europe
Germany, Italy, Poland, the UK, and Belgium are the key countries in Europe in the uterine leiomyoma (uterine fibroids) clinical trials market. Among them Italy has the highest number of clinical trials in the Uterine leiomyoma (uterine fibroids) Clinical trials market.
Uterine leiomyoma (uterine fibroids) clinical trials market in Middle East and Africa
Iran, Egypt, South Africa, Israel, and Lebanon are the key countries in Middle East & Africa in the Uterine leiomyoma (uterine fibroids) clinical trials market. Iran has the highest number of clinical trials.
Uterine leiomyoma (uterine fibroids) clinical trials market in North America
The US, Mexico and Canada are the key countries in North America in the Uterine leiomyoma (uterine fibroids) clinical trials market. Among them the US has the highest number of clinical trials.
Uterine leiomyoma (uterine fibroids) clinical trials market in Central and South America
Brazil, Chile, Cuba, Colombia, and Argentina are the key countries in Central and South America in the Uterine leiomyoma (uterine fibroids) clinical trials market. Among them Brazil has the highest number of clinical trials.
Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market, By Regions
For more regional insights, download a free report sample
G7 Countries Landscape In The Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market
The G7 countries include the US, Germany, France, Italy, Canada, the UK, and Japan. The US has the highest number of clinical trials.
Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market, by G7 Countries
For more G7 country insights, download a free report sample
E7 Countries Landscape In The Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market
The E7 countries include China, Russia, Brazil, Mexico, Turkey, Indonesia, and India. Among them China has the highest number of clinical trials.
Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market, By E7 Countries
For more E7 country insights, download a free report sample
Key Sponsors In The Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market
- AbbVie Inc
- Bayer AG
- Gedeon Richter Plc
- Neurocrine Biosciences Inc
- Sumitomo Chemical Co Ltd
- Sumitomo Pharma Co Ltd
- Sumitovant Biopharma, Inc.
- Takeda Pharmaceutical Co Ltd
- ObsEva SA
- Astellas Pharma Inc
Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Market, By Sponsors
To know more about sponsors, download a free report sample
Market report overview
Key regions | North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America, and Others |
Key sponsors | AbbVie Inc, Bayer AG, Gedeon Richter Plc, Neurocrine Biosciences Inc, Sumitomo Chemical Co Ltd, Sumitomo Pharma Co Ltd, Sumitovant Biopharma, Inc., Takeda Pharmaceutical Co Ltd, ObsEva SA, and Astellas Pharma Inc |
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
- Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
- Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Bayer AG
Gedeon Richter Plc
Neurocrine Biosciences Inc
Sumitomo Chemical Co Ltd
Sumitomo Pharma Co Ltd
Sumitovant Biopharma, Inc.
Takeda Pharmaceutical Co Ltd
ObsEva SA
Astellas Pharma Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the uterine leiomyoma (uterine fibroids) clinical trials market?
The key regions in the uterine leiomyoma (uterine fibroids) clinical trials market are North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America, and others.
-
Which are the key sponsors regions in the uterine leiomyoma (uterine fibroids) clinical trials market?
The key sponsors regions in the uterine leiomyoma (uterine fibroids) clinical trials market are AbbVie Inc, Bayer AG, Gedeon Richter Plc, Neurocrine Biosciences Inc, Sumitomo Chemical Co Ltd, Sumitomo Pharma Co Ltd, Sumitovant Biopharma, Inc., Takeda Pharmaceutical Co Ltd, ObsEva SA, and Astellas Pharma Inc
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.